OTCPK:QTXB

Stock Analysis Report

Executive Summary

QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States.

Snowflake

Fundamentals

Imperfect balance sheet with weak fundamentals.

Risks

  • QuantRx Biomedical is not covered by any analysts.

Share Price & News

How has QuantRx Biomedical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-15.1%

OTCPK:QTXB

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-25.0%

OTCPK:QTXB

9.9%

US Medical Equipment

1.6%

US Market

QTXB underperformed the Medical Equipment industry which returned 9.7% over the past year.

QTXB underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

QTXBIndustryMarket
7 Day-15.1%0.5%-0.02%
30 Day0%0.09%2.7%
90 Day-7.9%2.0%1.4%
1 Year-25.0%-25.0%10.8%9.9%3.8%1.6%
3 Year-35.7%-35.7%69.0%63.9%45.2%35.8%
5 Year-92.5%-92.5%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is QuantRx Biomedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is QuantRx Biomedical undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether QuantRx Biomedical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as QuantRx Biomedical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of QTXB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through QuantRx Biomedical regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is QuantRx Biomedical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as QuantRx Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of QTXB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access QuantRx Biomedical's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has QuantRx Biomedical performed over the past 5 years?

28.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

QuantRx Biomedical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare QuantRx Biomedical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare QuantRx Biomedical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if QuantRx Biomedical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if QuantRx Biomedical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if QuantRx Biomedical improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is QuantRx Biomedical's financial position?


Financial Position Analysis

QuantRx Biomedical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

QuantRx Biomedical has no long term commitments.


Debt to Equity History and Analysis

QuantRx Biomedical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if QuantRx Biomedical's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

QuantRx Biomedical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

QuantRx Biomedical has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if QuantRx Biomedical has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is QuantRx Biomedical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate QuantRx Biomedical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate QuantRx Biomedical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as QuantRx Biomedical has not reported any payouts.

Unable to verify if QuantRx Biomedical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as QuantRx Biomedical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of QuantRx Biomedical's salary, the management and board of directors tenure and is there insider trading?

US$31k

CEO Compensation


CEO

Shalom Hirschman (83yo)

8.8yrs

Tenure

US$31,000

Compensation

Dr. Shalom Z. Hirshman, M.D has been the Chairman at QuantRX Biomedical Corporation since September 7, 2010 and has been its Chief Executive Officer and Principal Accounting Officer since December 31, 2010 ...


CEO Compensation Analysis

Shalom's remuneration is lower than average for companies of similar size in United States of America.

Shalom's compensation has been consistent with company performance over the past year, both up more than 20%.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Shalom Hirschman (83yo)

    Chairman of the Board

    • Tenure: 8.8yrs
    • Compensation: US$31.00k

Board Members

  • Shalom Hirschman (83yo)

    Chairman of the Board

    • Tenure: 8.8yrs
    • Compensation: US$31.00k
  • Michael Abrams (49yo)

    Director

    • Tenure: 7.5yrs
    • Compensation: US$12.50k

Company Information

QuantRx Biomedical Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: QuantRx Biomedical Corporation
  • Ticker: QTXB
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$354.134k
  • Shares outstanding: 78.70m
  • Website: https://null

Location

  • QuantRx Biomedical Corporation
  • 10190 SW 90th Avenue
  • Tualatin
  • Oregon
  • 97123
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QTXBOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 1988

Biography

QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:53
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.